RESUMO
Essentials During contact system activation, factor XII is progressively cleaved by plasma kallikrein. We investigated the role of factor XII truncation in biochemical studies. Factor XII contains naturally occurring truncating cleavage sites for a variety of enzymes. Truncation of factor XII primes it for activation in solution through exposure of R353. SUMMARY: Background The contact activation system and innate immune system are interlinked in inflammatory pathology. Plasma kallikrein (PKa) is held responsible for the stepwise processing of factor XII (FXII). A first cleavage activates FXII (into FXIIa); subsequent cleavages truncate it. This truncation eliminates its surface-binding domains, which negatively regulates surface-dependent coagulation. Objectives To investigate the influence of FXII truncation on its activation and downstream kallikrein-kinin system activation. Methods We study activation of recombinant FXII variants by chromogenic assays, by FXIIa ELISA and western blotting. Results We demonstrate that FXII truncation primes it for activation by PKa in solution. We demonstrate this phenomenon in three settings. (i) Truncation at a naturally occurring PKa-sensitive cleavage site, R334, accelerates FXIIa formation in solution. A site-directed mutant FXII-R334A displays ~50% reduced activity when exposed to PKa. (ii) A pathogenic mutation in FXII that causes hereditary angioedema, introduces an additional plasmin-sensitive cleavage site. Truncation at this site synergistically accelerates FXII activation in solution. (iii) We identify new, naturally occurring cleavage sites in FXII that have so far not been functionally linked to contact system activation. As examples, we show that non-activating truncation of FXII by neutrophil elastase and cathepsin K primes it for activation by PKa in solution. Conclusions FXII truncation, mediated by either pathogenic mutations or naturally occurring cleavage sites, primes FXII for activation in solution. We propose that the surface-binding domains of FXII shield its activating cleavage site, R353. This may help to explain how the contact system contributes to inflammatory pathology.
Assuntos
Coagulação Sanguínea , Fator XII/metabolismo , Fator XIIa/metabolismo , Calicreína Plasmática/metabolismo , Catepsina K/metabolismo , Ativação Enzimática , Fator XII/genética , Fator XIIa/genética , Células HEK293 , Humanos , Elastase de Leucócito/metabolismo , Mutação , Domínios Proteicos Ricos em Prolina , Domínios e Motivos de Interação entre Proteínas , Especificidade por Substrato , Fatores de TempoAssuntos
Angioedemas Hereditários , Bradicinina , Proteína Inibidora do Complemento C1 , Humanos , PlasmaRESUMO
The plasma contact system contributes to thrombosis in experimental models. Even though our standard blood coagulation tests are prolonged when plasma lacks contact factors, this enzyme system appears to have a minor (if any) role in hemostasis. In this review, we explore the clinical phenotype of C1 esterase inhibitor (C1-INH) deficiency. C1-INH is the key plasma inhibitor of the contact system enzymes, and its deficiency causes hereditary angioedema (HAE). This inflammatory disorder is characterized by recurrent aggressive attacks of tissue swelling that occur at unpredictable locations throughout the body. Bradykinin, which is considered to be a byproduct of the plasma contact system during in vitro coagulation, is the main disease mediator in HAE. Surprisingly, there is little evidence for thrombotic events in HAE patients, suggesting mechanistic uncoupling from the intrinsic pathway of coagulation. In addition, it is questionable whether a surface is responsible for contact system activation in HAE. In this review, we discuss the clinical phenotype, disease modifiers and diagnostic challenges of HAE. We subsequently describe the underlying biochemical mechanisms and contributing disease mediators. Furthermore, we review three types of HAE that are not caused by C1-INH inhibitor deficiency. Finally, we propose a central enzymatic axis that we hypothesize to be responsible for bradykinin production in health and disease.
Assuntos
Angioedemas Hereditários/sangue , Coagulação Sanguínea/fisiologia , Bradicinina/fisiologia , Idade de Início , Angioedemas Hereditários/enzimologia , Angioedemas Hereditários/etiologia , Angioedemas Hereditários/fisiopatologia , Bradicinina/biossíntese , Permeabilidade Capilar , Ativação do Complemento , Proteína Inibidora do Complemento C1/fisiologia , Fator XIIa/fisiologia , Feminino , Angioedema Hereditário Tipos I e II/sangue , Angioedema Hereditário Tipos I e II/enzimologia , Angioedema Hereditário Tipos I e II/fisiopatologia , Humanos , Inflamação , Calidina/metabolismo , Calicreínas/fisiologia , Cininogênio de Alto Peso Molecular/metabolismo , Masculino , Modelos Biológicos , Fenótipo , Polifosfatos/metabolismo , Inibidores de Serina Proteinase/deficiência , Inibidores de Serina Proteinase/fisiologiaAssuntos
Endotoxemia/metabolismo , Mediadores da Inflamação/metabolismo , Cininogênio de Alto Peso Molecular/metabolismo , Lipopolissacarídeos/metabolismo , Animais , Coagulação Sanguínea , Endotoxemia/sangue , Endotoxemia/microbiologia , Endotoxemia/mortalidade , Humanos , Mediadores da Inflamação/sangue , Cininogênio de Alto Peso Molecular/sangue , Lipopolissacarídeos/sangue , Transdução de SinaisRESUMO
Hereditary angioedema (HAE) patients experience recurrent episodes of angioedema attacks that can be painful, disfiguring and even life-threatening. The disorder results from a mutation in the gene that controls the synthesis of C1-inhibitor (C1INH). C1INH is a major regulator of activation of the contact system. It is often assumed that attacks results from uncontrolled local activation of the contact system with subsequent formation of bradykinin. To evaluate the involvement of inflammatory reactions in HAE, we analysed C-reactive protein (CRP) levels. HAE patients included in a clinical database of recombinant human C1-inhibitor (rhC1INH) studies were evaluated. For the current study we analysed CRP levels when patients were asymptomatic, during a clinical attack and in a follow-up period, and correlated these with the clinical manifestations of the attack. Data from 68 HAE patients were analysed and included CRP levels on 273 occasions. While asymptomatic, 20% of the patients analysed had increased CRP. At the onset of the attack (P = 0·049) and during the next 24 h CRP rose significantly (P = 0·002) in patients with an abdominal location, and post-attack levels were significantly higher in these patients than in patients with attacks at other locations (P = 0·034). In conclusion, CRP levels are elevated in a substantial proportion of asymptomatic HAE patients. Levels of CRP increase significantly during an abdominal attack. These data suggest low-grade systemic inflammatory reactions in HAE patients as well as a triggering event for attacks that starts prior to symptom onset.